Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
NVTA - Invitae Corp.
$50.06
3.21(6.85%)6:00:01 PM 11/27/2020
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
Stock Chart

Summary:

  • MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    11/26/2020NVTA
    TSX Venture Exchange Stock Maintenance Bulletins

    VANCOUVER, BC, Nov. 26, 2020 /CNW/ -TSX VENTURE COMPANIESDEALNET CAPITAL CORP.

    11/24/2020NVTA
    3 Margin-Growing UK Stocks as Lockdown Measures Ease Up

    Episode 2 of World Travels Series aimed at finding margin growth companies

    11/24/2020NVTA
    Precision Medicine is Coming. What That Means for Patients and Investors.

    Dr. Charles Kennedy, CEO of Blue Ox Healthcare Partners, answers Barron’s readers’ questions on health-care innovation, delivery, and investing.

    11/24/2020NVTA
    We're Better Off Without the Black Friday Frenzy

    (Bloomberg Opinion) -- The Christmas lights are on, but few are coming to see them.That was the scene last week on Oxford Street, London’s leading retail thoroughfare, as non-essential shops in England remained closed. It’s hardly the run-up to Black Friday that retailers had hoped for. I’ve argued before that Europe is better off without the imported annual shopping frenzy. While door-busting deals are a post-Thanksgiving tradition in the U.S., there is no place for them on this side of the Atl...

    11/19/2020NVTA
    New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients

    Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials. Despite professional guidelines that recommend testing for all pancreatic cancer patients, it remains underutilized in routine care. The study was presented at the National Society of Genetic Counselors 39th Annua...

    11/10/2020NVTA
    Imagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 557% Higher

    Invitae Corporation (NYSE:NVTA) shareholders have seen the share price descend 17% over the month. But that doesn't...

    11/9/2020NVTA
    Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

    Genetic testing, educational materials and counseling offered at no charge to patientsPHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announce a collaboration to facilitate genetic testing and support early identification of GM1 gangliosidosis (GM1) through Invitae’s Detect ...

    11/7/2020NVTA
    Invitae (NVTA) Q3 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to Invitae's third-quarter 2020 financial results conference call. Joining us today are Sean George, our CEO; Shelly Guyer, our CFO; Lee Bendekgey, our chief policy officer; Bob Nussbaum, our chief medical officer; and Katherine Stueland, our chief commercial officer, and Jason Myers, president of our oncology business area. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical...

    11/6/2020NVTA
    7 Data-Driven Stocks for a Wave of Innovation

    Everyone is thinking of e-commerce, social media engagement, the 5G revolution — you name it. There are a lot of cool and inspiring trends in tech, and they happen so fast that it becomes very exciting. But shouldn’t we stop to recognize the data stocks in all of this? Data is now being created at an exponential rate. Text messages, direct messages, photos, comments, shopping habits, even the routes we take on the road or in a store generate data.  But here’s the problem: All of that data is wor...